Sikander Ailawadhi, MD
DISCLAIMER
The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
SUMMARY
This study assessed patient, caregiver, and healthcare provider perspectives on the burden of treatment-related side effects (SEs) and their influence on treatment decisions in chronic lymphocytic leukemia (CLL). Three online cross-sectional surveys were conducted from March to June 2026 among US adults with CLL who had experienced ≥1 SE from CLL treatment, unpaid adult caregivers of such patients, and healthcare providers involved in CLL management who had treated ≥5 patients with CLL in the prior 12 months. The study included 200 patients with CLL, 200 caregivers, and 200 healthcare providers. In the first-line setting, fatigue affected physical and social functioning (72% frequent sitting/lying down; 61% cancelled or declined social events; 48% loss of interest in hobbies). Diarrhea limited mobility and public activities (64% avoided time away from home; 63% felt embarrassed or self-conscious in public). Headache was associated with cancelled social events (52%) and difficulty concentrating (32%). Nausea/vomiting affected social participation and mobility (58% cancelled social events; 54% avoided time away from home). Joint/muscle pain affected physical functioning, including frequent sitting/lying down (42%) and sleep problems (42%). SE impacts in second-line and third-line or later settings were generally similar to those in the first-line setting. Caregivers frequently reported taking on more household responsibilities, providing transportation support, providing physical support, and reduced sleep or rest. Providers most frequently discussed the impact of SEs on physical functioning, with more than 60% discussing fatigue in detail, followed by nausea/vomiting (52%), diarrhea (51%), and headache (49%). Discussions of mental/emotional and social functioning impacts were generally less frequent, ranging from 21% to 54% across SE types.
Haitao Wang, PhD
Alvaro Alencar, MD
Nakhle S. Saba, MD
Are you a returning user?
LOGINFor new users, please select your country/region
This website is intended exclusively for healthcare professionals and is provided for scientific exchange and educational purposes only. It is not intended for patients or the general public and does not constitute advertising, promotional activity or medical advice.
Content may include information about products, indications or uses that are not approved in all countries or regions, and may be subject to local regulatory requirements.
By continuing, you confirm that you are a healthcare professional and acknowledge the above.
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed